Jefferies Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
October 24, 2024 7:43 AM EDTH.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $30.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst commented: "This morning, Olema presented three preclinical data posters at EORTC-NCI-AACR Symposium including combinations of OP-3136 with fulvestrant or palazestrant and/or CDK4/6 inhibitors, and combinations of palazestrant with everolimus (mTOR inhibitor) or capivasertib (pan-AKT inhibitor). As a reminder, OP-3136 is the company's KAT6 inhibitor, which is an emerging target for the treatment... More
Goldman Sachs Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
October 24, 2024 6:16 AM EDTGoldman Sachs analyst Richard Law reiterated a Buy rating and $27.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst comments "At the EORTC-NCi-AACR Symposium, OLMA presented preclinical in vitro and in vivo results for its KAT6 inhibitor OP-3136 vs. PFE's PF-07248144 as monotherapy, or in various doublet/triplet combinations with endocrine therapy (fulvestrant or pala) and/or CDK4/6i (ribociclib). For the... More
